What is the difference between commodity chemicals and specialty chemicals?

Commodity chemicals are produced in very large volumes, using well-understood processes, and sold largely on price because the product from one supplier is largely interchangeable with another's. Examples include chlorine, caustic soda, methanol, and standard solvents. Specialty chemicals, by contrast, are produced in smaller volumes for specific end-use applications, often involve proprietary synthesis routes or formulations, and command a price premium because of performance characteristics or application-specific suitability. Examples include specialty dyes and pigments for high-end paints, performance chemicals for semiconductor manufacturing, or active pharmaceutical ingredients produced to precise specifications. The financial difference is material: specialty chemicals typically generate EBITDA margins of 20%–35% while commodity chemicals might generate 10%–15%.

What was the China+1 thesis and did it benefit Indian chemical companies?

The China+1 thesis was the observation — gaining momentum from around 2018 and accelerating sharply after the COVID-19 pandemic in 2020 — that global manufacturers of chemicals, pharmaceuticals, and electronics wanted to reduce their dependence on Chinese supply chains. China had built dominant positions in many chemical supply chains (specialty intermediates, active pharmaceutical ingredients, dyes, agrochemical actives) through the 2000s and 2010s. Customers who had consolidated sourcing into China for cost reasons found themselves exposed when Chinese supply was disrupted by COVID-19, environmental shutdowns, or geopolitical tensions. India was seen as one of the most credible alternative supply bases given its existing chemical industry base, English-language engineering talent, and intellectual property framework. Indian specialty chemical companies — particularly those in fluorine chemistry, CRAMS, and agrochemical intermediates — were significant beneficiaries of this thesis in the 2020–2023 period.

What is CRAMS in the context of Indian chemicals?

CRAMS stands for Contract Research and Manufacturing Services. In the chemical and pharmaceutical context, it refers to companies that conduct chemical research and synthesise compounds for external clients — typically global agrochemical or pharmaceutical companies — under long-term contracts. The client company (typically a multinational) designs the molecule or the active ingredient; the CRAMS provider figures out how to make it at scale, builds the manufacturing facility, and produces it on a contracted basis. CRAMS businesses tend to generate higher margins than commodity chemical production because of the proprietary nature of the synthesis and the long-term nature of client relationships. PI Industries was a notable Indian listed example of a company with a significant CRAMS business in agrochemical intermediates.

How do crude oil and naphtha prices affect Indian chemical companies?

Naphtha (a petrochemical feedstock derived from crude oil refining) and other hydrocarbon derivatives are the primary raw materials for a large proportion of Indian chemical production — including solvents, polymers, and many organic chemical intermediates. When crude oil prices rise, naphtha and downstream feedstock costs rise with them. For commodity chemical producers that cannot easily pass costs through, margin compression results. For specialty chemical producers with long-term customer contracts, the ability to pass through raw material cost increases depends on contract terms — some have price escalation clauses, others operate on fixed prices and must absorb input inflation. Understanding a specific company's feedstock exposure and pricing power is therefore essential to predicting margin trajectory across commodity cycles.

What is ZLD (Zero Liquid Discharge) and why does it matter for chemical companies?

Zero Liquid Discharge (ZLD) is an environmental compliance standard mandated by India's pollution control authorities (the Central Pollution Control Board and State PCBs) for certain industries, primarily textile dyeing and some chemical manufacturing. ZLD requires that a plant treat and recycle all process wastewater internally, with no liquid effluent discharged to rivers, groundwater, or public drainage. Achieving ZLD requires significant capital investment in evaporation systems, reverse osmosis, and effluent treatment plants. For chemical companies in heavily regulated states (especially Gujarat and Maharashtra), ZLD compliance was a meaningful capex requirement. Companies that failed to comply faced closure orders. Analysts monitoring chemical companies therefore tracked environmental compliance status as an operational risk factor.

Chemical Sector in India: Specialty, Commodity, and China+1

India's chemical industry: a structural overview

India's chemical industry was, as of the mid-2020s, among the largest in the world by volume — ranking around sixth globally — with a significant base in Gujarat (which hosted the bulk of the industry's manufacturing capacity) and a growing presence in Maharashtra, Rajasthan, and other states. The industry was structured around three broad categories that had very different financial characteristics.

Commodity chemicals

Commodity chemicals are produced at very large volumes using established, well-understood processes. The product is undifferentiated — one producer's chlorine or soda ash is the same as another's — so pricing is set by global supply and demand dynamics. These businesses are capital-intensive, cyclical, and generally earn lower returns on capital than specialty chemical peers during normal conditions (though they can generate exceptional returns at cycle peaks when supply is tight).

Key Indian commodity chemical sub-segments included chlor-alkali (chlorine and caustic soda — important inputs for paper, textiles, and water treatment), soda ash (glass and detergent manufacturing), and standard solvents. Tata Chemicals was a major Indian listed company in commodity chemicals, with soda ash operations in India, the UK, and the United States. Deepak Nitrite's phenol and acetone business was also commodity-oriented, though the company had significant specialty chemical revenues as well.

Specialty chemicals

Specialty chemicals are defined by application specificity and product differentiation. A specialty dye formulated for a particular high-performance textile is not interchangeable with a generic dye; a fluorinated agrochemical intermediate synthesised to a specific molecular structure is the product of a complex, protected synthesis route. Specialty chemicals companies earn their premium margins from proprietary processes, application expertise, long-term customer relationships, and — in some cases — intellectual property protection.

India's specialty chemical sector expanded rapidly in the 2015–2023 period, driven by a combination of: domestic demand growth across end-user industries (agrochemicals, textiles, pharma, plastics); China+1 supply chain diversification by global manufacturers; and heavy capital investment by Indian companies to build new capacity.

Agrochemicals

Agrochemicals — pesticides, herbicides, and fungicides — occupy a unique position straddling commodity and specialty. Generic active ingredients (off-patent molecules like glyphosate, cypermethrin, or mancozeb) are produced by multiple manufacturers and compete largely on price. Patented active ingredients — developed by multinationals like Syngenta, Corteva, BASF, or Bayer — are more differentiated but require a royalty arrangement or licence to manufacture.

India was a significant agrochemical exporter, particularly of generic active ingredients and technical-grade actives. The large domestic agricultural base also created a substantial domestic market. UPL (formerly United Phosphorus) was the largest listed Indian agrochemical company and had a genuinely global business through acquisitions of Arysta LifeScience and other international companies.

The China+1 thesis: what it was and what it drove

To understand the specialty chemicals investment cycle of the early 2020s in India, the China+1 thesis is the central frame.

China had built a globally dominant position in chemical manufacturing through the 2000s and 2010s through a combination of cheap labour, government-subsidised industrial parks, low environmental compliance costs (historically), and the scale advantages of integrating enormous industrial clusters. Chinese suppliers came to dominate supply chains for: dyes and pigments (where Chinese companies captured the bulk of global production after Indian and European manufacturers faced environmental pressure), active pharmaceutical ingredients (API) and intermediates, agrochemical actives, and electronic chemicals.

The risks of this concentration became visible in several episodes:

China's environmental enforcement campaign of 2017–18, which temporarily shut down numerous chemical factories in Shandong and other provinces, caused supply disruptions and price spikes for customers globally.
The COVID-19 pandemic in early 2020 caused factory shutdowns across China, disrupting supply chains for pharmaceutical and agricultural inputs globally. Companies in Europe, North America, and Japan that had consolidated sourcing in China found themselves without supply.
Escalating US-China trade tensions, including the imposition of tariffs and export controls in various sectors, raised the geopolitical cost of single-source China dependence.

The cumulative effect was a deliberate effort by global chemical and pharmaceutical companies to qualify and develop alternative supply sources — with India as the most credible large-scale alternative given its established chemical manufacturing base, English-language technical talent, and regulatory framework (particularly the US FDA and European regulatory approvals already held by Indian pharmaceutical companies).

Indian specialty chemical companies — particularly those in fluorine chemistry, CRAMS, and agrochemical intermediates — reported strong order flows and volume growth as global customers accelerated their qualification and sourcing diversification from 2020 onward. This drove a significant capacity expansion cycle.

Key sub-segments

Dyes and pigments

India was historically a major manufacturer of dyes and pigments for textiles, leather, and industrial applications. The Vapi-Ankleshwar industrial corridor in south Gujarat was the historical hub. Dyes and pigments had historically been a challenging business due to intense pricing competition from Chinese producers and significant environmental compliance requirements (ZLD, hazardous waste management). The business was consolidating toward larger, more compliant operators while smaller units struggled with environmental capital costs.

Fluorine chemistry

Fluorine-containing compounds — organofluorine chemicals — have specific and valuable properties (stability, resistance to heat and chemicals, biological activity) that make them critical inputs in agrochemicals (some of the most effective modern pesticides are fluorinated), pharmaceuticals (fluorine often improves drug bioavailability), refrigerants (HFCs), and advanced materials.

India had limited fluorite (the primary fluorine mineral) deposits but developed a significant fluorine chemistry manufacturing base in Gujarat. SRF and Navin Fluorine were the two principal listed Indian companies with deep fluorine chemistry capabilities. Both companies benefited from China+1 demand and significant CRAMS contract wins in fluorinated agrochemical intermediates.

Agrochemical intermediates and CRAMS

The agrochemical CRAMS segment in India — where Indian companies manufactured patented or proprietary agrochemical intermediates for global multinational clients under long-term contracts — was the most high-profile beneficiary of China+1. PI Industries was the most notable listed example, with a CRAMS business that consisted of multi-year exclusive contracts with global agrochemical multinationals. The company's CRAMS export revenue grew strongly as global majors diversified sourcing from China.

Pharma intermediates

Similar to agrochemical CRAMS, Indian chemical companies manufactured pharmaceutical intermediates (building blocks used in API synthesis) for global pharmaceutical customers. The pharma supply chain was an early and significant beneficiary of China+1 concerns, given the national security dimensions of drug supply security highlighted during COVID-19. Companies like Aarti Industries had significant pharmaceutical intermediate revenues alongside their performance chemical business.

Key financial metrics

Revenue growth and mix

Revenue growth trajectory is important, but mix matters as much as headline growth. A company whose revenue is growing because commodity chemical volumes are up in a favourable pricing cycle is in a fundamentally different position from one whose growth is driven by specialty CRAMS contracts with long-term pricing commitments. Analysts tracking the specialty chemical sector historically paid close attention to the export vs domestic split, and the CRAMS vs spot-market sales split within export revenues.

EBITDA margin and its sustainability

EBITDA margins ranged widely across the sector: commodity producers historically in the 10%–18% range; mid-quality specialty producers in the 18%–25% range; fluorine chemistry and CRAMS leaders in the 25%–35%+ range. The key analytical question was always whether a company's current margin was sustainable or was elevated due to a temporary supply-demand imbalance.

A significant concern that emerged in 2023–24 was margin compression across parts of the specialty chemical sector as the capex cycle of 2020–2023 (enormous new capacity was added both in India and elsewhere, and some Chinese capacity that had been shut came back online) resulted in oversupply in certain intermediate chemicals. Companies whose revenue growth had been driven by one-time sourcing diversification saw volumes moderate as customers worked down inventory.

R&D spend

For specialty chemical companies, R&D spending — typically expressed as a percentage of revenue — signals the investment in the product development pipeline that underpins future growth. CRAMS businesses require process development capabilities; new molecule synthesis capabilities command premium pricing. Companies like Clean Science and Technology built entire businesses on proprietary green-chemistry synthesis routes for products historically made through environmentally problematic processes.

Capex intensity and asset turns

The chemical sector is capital-intensive. Multipurpose batch reactors, continuous process plants, distillation columns, effluent treatment systems, and storage infrastructure all require significant fixed capital. Capex intensity — capex as a percentage of revenue, or the growth capex needed to add each rupee of incremental revenue — varied by sub-segment. Companies with high asset turns (generating high revenue per rupee of fixed assets) and high ROCE were historically rewarded with premium valuations.

ROCE (Return on Capital Employed)

ROCE is the critical quality metric for chemical businesses. Because the sector is capital-intensive, a company earning good EBITDA margins but investing heavily in fixed assets and working capital may generate mediocre ROCE. The best Indian specialty chemical businesses — Clean Science, Navin Fluorine's specialty segment, PI Industries' CRAMS business — historically generated ROCE in the 25%–40% range. Commodity-oriented producers were typically in the 12%–18% range.

Major listed players

SRF Limited

SRF was a diversified specialty chemical company with major businesses in fluorochemicals (refrigerants and fluorine chemistry intermediates), specialty chemicals (CRAMS-type agrochemical and pharmaceutical intermediates), technical textiles (tyre cord fabric, belting fabric), and packaging films. Its chemicals business was the fastest-growing and highest-margin segment. SRF invested heavily in fluorine chemistry capacity through the early 2020s to capture CRAMS demand.

Aarti Industries

Aarti Industries was one of India's largest benzene-based specialty chemical companies, manufacturing a wide range of nitro-chloro aromatics, amines, and their derivatives for agrochemicals, pharmaceuticals, dyes, and polymers. The company had a notable long-term supply agreement with a global chemical major for dedicated specialty products — a contract that provided revenue visibility. Aarti also had a pharmaceutical API subsidiary.

PI Industries

PI Industries operated two distinct businesses: a domestic agrochemical distribution business (selling crop protection products to Indian farmers) and a CRAMS export business manufacturing patented agrochemical intermediates for global multinationals. The CRAMS business was the primary growth and margin driver, with a multi-year order book and revenue visibility. PI was often cited as a benchmark example of the China+1 beneficiary thesis in the Indian chemical sector.

Navin Fluorine International

Navin Fluorine was a fluorine chemistry specialist with businesses in commodity refrigerants (HFCs and HFOs), specialty fluorochemicals (for agrochemicals, pharmaceuticals, and electronics), and high- performance products (including PTFE and other advanced fluoropolymers). The company invested in a dedicated CRAMS capacity for high-value fluorinated intermediates.

Clean Science and Technology

Clean Science was an IPO-stage company (listed in 2021) with proprietary green-chemistry processes for producing specialty chemicals like MEHQ (monomethyl ether hydroquinone), BHA (butylated hydroxyanisole), and anisole. Its distinguishing feature was that it used catalytic oxidation processes that were significantly more environmentally benign than conventional routes, which also happened to be more cost-competitive. This gave it structural cost advantages in its product categories.

Deepak Nitrite

Deepak Nitrite had a diversified chemical portfolio including performance products (sodium nitrite, nitro toluenes — inputs for dyes, rubber chemicals, and pharma), and a major phenol and acetone plant that came on stream in 2018. The phenol/acetone plant was commodity-oriented but produced import substitution at scale for the Indian market. The company also had a subsidiary (Deepak Phenolics) dedicated to this plant.

UPL Limited

UPL was the largest Indian agrochemical company by revenue, with a global footprint built through acquisitions — most significantly the 2019 acquisition of Arysta LifeScience, which transformed UPL into a top-five global agrochemical company. The acquisition was debt-funded, creating a highly leveraged balance sheet that became a source of investor concern as the agrochemical cycle softened in 2023.

Tata Chemicals

Tata Chemicals was predominantly a commodity chemical company — soda ash, sodium bicarbonate, and salt — with operations across India, the UK (Tata Chemicals Europe), and the US (previously, before divesting). It also had a nascent specialty chemicals and agribusiness (seed treatment) division. Its earnings were more commodity-linked and cyclical than the specialty chemical peers.

The 2020–2024 capex cycle: context

The China+1 thesis and strong demand from agrochemical and pharmaceutical customers drove a significant capacity investment cycle among Indian specialty chemical companies from approximately 2020 to 2024. Companies that had been running at high capacity utilisation — receiving strong pricing signals from the market — invested heavily in greenfield and brownfield capacity expansion.

This capex cycle was capital-intensive and time-consuming: chemical plant construction typically takes 18–30 months from decision to commissioning, depending on complexity. The plants that were commissioned from 2023 onward entered service into a market that had changed: inventory destocking by global customers, some normalisation in Chinese supply capacity, and slower-than-expected volumes in certain product categories.

The result, visible in company financials through 2023–24, was a period of margin pressure and capacity underutilisation in parts of the sector — a textbook post-capex-cycle normalisation. Companies with long-term CRAMS contracts and locked-in customer relationships were more insulated than those selling into spot markets.

Environmental regulations and compliance

India's chemical industry has historically been at the centre of environmental regulation debates. Industrial clusters in Gujarat and Maharashtra were among the most significant sources of industrial water pollution — historically discharging into rivers, coastal zones, and groundwater.

ZLD mandates

Zero Liquid Discharge (ZLD) mandates — requiring that all wastewater be treated and recycled with no effluent discharge — have been progressively implemented for chemical, textiles, and other polluting industries in India. Achieving ZLD compliance required installing effluent treatment plants, multi-effect evaporators, reverse osmosis systems, and crystallisers — a capital cost that smaller, less well-funded operators struggled to bear. The regulatory push for ZLD compliance acted as a consolidation catalyst, favouring larger, better-capitalised companies and squeezing out marginal players.

Pollution control closures

The Gujarat Pollution Control Board and Maharashtra Pollution Control Board have issued closure notices to chemical units found in violation of environmental standards. The threat of closure and the reputational and operational cost of enforcement actions created an incentive for larger listed companies to invest in compliance infrastructure. Analysts monitoring chemical companies tracked compliance status as a tail risk — particularly for companies in heavily regulated clusters where GPCB activity was more intense.

Pricing dynamics

Commodity chemicals: crude and naphtha linkage

Commodity chemical prices are driven by global supply-demand balances and are heavily influenced by crude oil prices through naphtha and other petrochemical feedstocks. When oil prices rise sharply, input costs rise for commodity chemical producers. Whether they can pass these increases through depends on the tightness of global supply — in a tight market, they can; in an oversupplied market, they absorb the increase.

Analysts modelling commodity chemical companies therefore spend significant effort understanding feedstock cost pass-through mechanisms, the company's position in the global cost curve, and the cyclical position of the relevant end markets.

Specialty and CRAMS: contracted pricing

Specialty chemical and CRAMS companies often operate under long-term supply agreements with fixed or formula-based pricing. These contracts typically include raw material cost escalation clauses that allow the supplier to pass through documented input cost increases to the customer. The quality and coverage of these escalation clauses is an important but often under-disclosed contract detail that affects the stability of margins.

New molecule CRAMS in particular can command premium pricing because the synthesis is complex and proprietary — the customer has limited ability to quickly qualify an alternate supplier. This pricing power tends to be highest in the first few years after a new molecule is qualified.

Nifty 500 companies in this sector

The chemicals sector within the Nifty 500 universe included companies spanning commodity chemicals, specialty chemicals, agrochemicals, and fluorine chemistry. Company profiles for individual Nifty 500 constituents — including historical financials, EBITDA margins, ROCE, and capex data — are available in our stock profiles section. When reading those profiles, the metrics framework and sub-segment context discussed in this primer provides the analytical foundation for interpreting the numbers meaningfully.

This article is educational only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. All company descriptions and historical observations are illustrative and reflect past conditions; past performance is not indicative of future results. Stock markets involve risk, including the loss of principal. Please consult a SEBI-registered investment adviser before making any investment decision.